This clinical trial is focused on studying a condition known as adnexal torsion, which occurs when an ovary or fallopian tube twists, potentially cutting off its blood supply. The study will use a special imaging technique called contrast enhanced ultrasound to help diagnose this condition. The contrast agent used in this study is called SonoVue, which contains a substance known as sulfur hexafluoride. This agent is injected into the bloodstream to improve the clarity of ultrasound images.

The purpose of the study is to evaluate whether using contrast enhanced ultrasound can improve the accuracy of diagnosing adnexal torsion compared to the standard method, which does not use contrast. Participants in the study will be randomly assigned to one of two groups: one group will receive the contrast enhanced ultrasound, and the other will undergo the standard diagnostic procedure. The study aims to determine if the new method can reduce unnecessary surgeries by providing clearer diagnostic information.

Throughout the study, participants will be monitored for any immediate or delayed reactions to the contrast agent, as well as for any complications related to the condition or its treatment. The study will also track the rate of hospitalizations, consultations, and any additional surgeries needed within a month after the initial diagnosis. The goal is to gather data that could help improve the diagnostic process for adnexal torsion and potentially lead to better outcomes for patients experiencing this condition.